罗格列酮联合二甲双胍治疗2型糖尿病的临床疗效分析

目的观察罗格列酮联合二甲双胍治疗2型糖尿病的临床疗效。方法 80例2型糖尿病患者,随机分为观察组（罗格列酮联合二甲双胍）和对照组（二甲双胍）各40例。观察比较两组治疗前后空腹血糖（FBG）、餐后2h血糖（2hPG）与糖化血红蛋白（HbA1c）的变化情况。结果观察组的总有效率达95.0%,对照组仅为75.0%,两组疗效比较,差异有统计学意义（P〈0.05）。两组治疗前FBG、2hPG、糖化血红蛋白（HbA1c）比较,差异无统计学意义（P〉0.05）,治疗3个月后两组FBG、2hPG、HbA1c均较治疗前明显降低,且观察组较对照组降低更显著（P〈0.05）。结论罗格列酮联合二甲双胍治疗2型糖尿病疗效确切,能有效的控制血糖,且不良反应少,值得广泛推广和应用。     

Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed,untreated diabetes and IGT patients: 1-year randomised,double-blind,placebo-controlled study

Objective To investigate whether pharmacological interventions with rosiglitazone/ramipril can reverse preclinical vasculopathy in newly diagnosed untreated patients with type 2 diabetes (T2DM) and impaired glucose tolerance (IGT). Methods In this randomised, double-blind, placebo-controlled study, 33 T2DM and 33 IGT patients were randomised to 4 mg rosiglitazone or 5 mg ramipril or placebo for 1 year. The subjects were newly diagnosed, untreated, normotensive, nonobese, nonsmoker, and nonhyperlipidaemic. Haemodynamic variables were measured at three treatment phases and pulse wave velocity (PWV) and augmentation index (AI) were measured throughout the treatment period. Results Rosiglitazone showed a significant reduction in PWV (p=0.039) and AI (p=0.031) and ramipril demonstrated a significant reduction of AI (p=0.025) in IGT in comparison to placebo on the 12th month of treatment. No significant difference was observed in PWV and AI in T2DM with rosiglitazone/ramipril in comparison to placebo during overall treatment period. Conclusions Rosiglitazone significantly reversed preclinical vasculopathy in IGT as evident by significant decrease in PWV and AI after 1 year of treatment. Ramipril also reduced large artery stiffness as shown by significant decrease of AI after 1 year of treatment in IGT. Further trials are needed for a longer period of time, maybe with higher doses, to show whether rosiglitazone/ramipril can reverse preclinical vasculopathy in T2DM.     

Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes

Subjects (N = 22,808) with inadequately controlled type 2 diabetes mellitus (T2DM) were included in a large 6-month observational study in Germany. Rosiglitazone (RSG) was added to existing therapy in line with daily practice, with 19,962 subjects evaluated for efficacy by treatment group: RSG monotherapy (n = 1017), RSG plus metformin (MET) (n = 7160), RSG plus sulphonylurea (n = 5033), triple oral therapy (n = 4247), and the remaining subject population (n = 2505). Overall, RSG significantly reduced median HbA(1c) and fasting blood glucose by 1.3% and 50 mg/dl over 6 months (p < 0.001 for both). The proportion of subjects achieving glycaemic goals of 相似文献   

马来酸罗格列酮对合并糖尿病的冠心病患者部分炎症指标的影响

目的观察应用马来酸罗格列酮对合并糖尿病的冠心病患者体内部分炎症因子水平的影响。方法30例合并有2型糖尿病的冠心病患者在原有治疗的基础上加用马来酸罗格列酮治疗,治疗前及治疗3个月后分别检测空腹血糖(FPG)、血胰岛素(FIns)、糖化血红蛋白(HbA1c),C反应蛋白(CRP),肿瘤坏死因子a(TNFa)和可溶性白介素2受体(SIL-2R),比较各指标的变化。结果马来酸罗格列酮治疗3个月后患者的CRP、TNFa、SIL-2R出现显著下降(P<0.01),FPG、FIns、HbA1c亦显著下降(P<0.01;P<0.05),胰岛素敏感性指数则明显上升(P<0.05)。结论在合并2型糖尿病的冠心病患者中应用马来酸罗格列酮治疗,不仅可以改善其糖代谢,还可降低患者体内部分炎症因子的水平,可能对冠心病患者的预后有益。     

罗格列酮对2型糖尿病合并稳定型心绞痛血脂水平的影响

目的探讨罗格列酮对2型糖尿病合并稳定型心绞痛病人血脂水平的影响。方法2型糖尿病合并稳定型心绞痛病人58例,随机分人对照组和罗格列酮组。对照组采用原来降血糖药和冠心病二级预防药作常规治疗,不加用罗格列酮。罗格列酮组在原来降血糖药的基础上给予罗格列酮4mg口服,每日1次,共30日。治疗前后分别测定血清总胆固醇,甘油三酯,高密度脂蛋白胆固醇和低密度脂蛋白胆固醇水平。结果治疗30日后,两治疗组血脂水平血清总胆固醇,甘油三酯,低密度脂蛋白胆固醇,载脂蛋白A和载脂蛋白B均有不同程度的下降,高密度脂蛋白胆固醇升高,但两组的改变程度差异有统计学意义（P〈0．05）。结论罗格列酮在常规治疗的基础上可以使血脂水平进一步改善,使2型糖尿病合并稳定型心绞痛病人受益。     

The protective effect of rosiglitazone on renal injury of severe acute pancreatitis北大核心CSCD

Objective: To investigate the effects of rosiglitazone, the agent of highly selective peroxisome proliferator - activated receptor - γ agonist, on the renal injury of rats with severe acute pancreatitis. Methods: Fifty - four male Wistar rats were randomly (random number) divided into three groups: sham operation group (SO group), severe acute pancreatitis group (SAP group) and rosiglitazone pretreatment group (ROSI group). Severe acute pancreatitis model was induced by retrograde infusion of 5% sodium taurocholate into the biliopancreatic duct. Rosiglitazone (6 mg/kg) dissolved in 10% DMSO were injected into the femoral vein 30 minutes prior to the modeling. The solution of 10% DMSO was given to rats of SO group and SAP group. Rats were sacrificed 3, 12 and 24 h after modeling. The levels of serum amylase, serum creatinine, urea nitrogen, urinary albumin, urinary IgG and α1 - microglobulin were measured and analyzed statistically. Kidney tissue samples were stained respectively with hematoxylin and eosin for histopathological evaluation. Results: The levels of serum amylase, serum creatinine, urea nitrogen, urinary albumin, urinary IgG and α1-microglobulin were significantly increased (P < 0. 05) after modeling, while lesser increases were found in ROSI group 12 h and 24 h after modeling (P <0. 05) compared with those in SAP group. Conclusions: Renal injury can be induced by severe acute pancreatitis, while Rosiglitazone protects rats from renal injury in the setting of severe acute pancreatitis.     

The antidiabetic plants Tecoma stans (L.) Juss. ex Kunth (Bignoniaceae) and Teucrium cubense Jacq (Lamiaceae) induce the incorporation of glucose in insulin-sensitive and insulin-resistant murine and human adipocytes

Aim of the study

Tecoma stans (L.) Juss. ex Kunth (Bignoniaceae) and Teucrium cubense Jacq (Lamiaceae) are plants extensively used for the empirical treatment of diabetes mellitus, but their antidiabetic mechanisms remain to be clarified. In this study, the effect of aqueous extracts of Tecoma stans (TSE) and Teucrium cubense (TCE) on the glucose uptake in adipose cells was evaluated.

Materials and methods

Non-toxic concentrations of TSE and TCE were assayed on the adipogenesis and 2-NBDglucose uptake in insulin-sensitive and insulin-resistant murine 3T3-F442A and human subcutaneous adipocytes.

Results

Both extracts stimulated 2-NBDG uptake by insulin-sensitive and insulin-resistant adipocytes in a concentration-dependent manner. In insulin-sensitive cells, TSE 70 μg/ml stimulated 2-NBDG uptake by 193% (murine) and by 115% (human), whereas the same concentration of TCE induced the 2-NBDG uptake by 112% (murine) and 54% (human). In insulin-resistant adipocytes, TSE induced the 2-NBDG uptake by 94% (murine) and 70% (human), compared with the incorporation shown by insulin-sensitive adipocytes stimulated by the hormone, whereas TCE induced the incorporation of 2-NBDG by 69% (murine) and 31% (human). On the other hand, TSE and TCE exerted only minimal or null proadipogenic effects on murine and human preadipocytes.

Conclusion

Tecoma stans and Teucrium cubense exert their antidiabetic effects stimulating glucose uptake in both insulin-sensitive and insulin-resistant murine and human adipocytes without significant proadipogenic or antiadipogenic side effects.     

短期罗格列酮钠治疗对2型糖尿病腹部脂肪分布的影响

目的：观察短期罗格列酮钠治疗对2型糖尿病患者腹内脂肪分布的影响,并与进口马来酸罗格列酮片做比较.方法：36例磺脲类药物疗效不佳的2型糖尿病患者随机分为两组,A组加用罗格列酮钠和B组加用马来酸罗格列酮,疗程12w,于试验前及试验结束时用CT测定L4水平腹内及腹部皮下脂肪面积.结果：无论是A组还是B组,与治疗前相比12w时空腹血糖（FPG）、餐后2h血糖（PPG）、空腹胰岛素、糖化血红蛋白（HbAlc）、HOMA-IR显著下降（P＜0.05）;治疗12w后两组腹内脂肪面积、腹内脂肪面积/腹部皮下脂肪面积比值显著下降（P＜0.05）,腹部皮下脂肪面积显著增加（P＜0.05）;治疗后两组患者C-反应蛋白均明显下降（P＜0.001）;治疗后血游离脂肪酸、血脂两组都无明显变化.结论：短期罗格列酮钠治疗能减少2型糖尿病患者腹内脂肪,促进内脏脂肪向皮下转移.     

2型糖尿病应用罗格列酮前后CRP WBC变化

目的观察应用罗格列酮对2型糖尿病（T2DM）患者体内C反应蛋白（CRP）及白细胞（WBC）水平的影响。方法89例已合用磺脲类和双胍类药物的T2DM患者采用随机、双盲、安慰剂、平行对照方法分至罗格列酮组及安慰剂组,进行3个月的临床观察,治疗前及治疗3个月后分别检测空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbAlc）、胆固醇（TC）、甘油三脂（TG）、低密度脂蛋白（LDL—C）、高密度脂蛋白（HDL—c）、血胰岛素（Fins）、C反应蛋白（CRP）、白细胞计数（WBC）,比较各指标的变化,另外选择同期检查的健康志愿者44例作为健康对照组。结果罗格列酮治疗3个月后患者的CRP、WBC出现显著下降（P〈0．01）,FPG、2hPG、HbAlc、TG、HOMA—IR亦显著下降（P〈0．05）,HDL—C则明显上升（P〈0、05）。结论T2DM患者应用罗格列酮治疗,不仅可以改善其糖脂代谢,还可降低患者体内部分炎症因子的水平。可能对2型糖尿病患者预防慢性并发症有益。     

罗格列酮对糖尿病大鼠肾脏氧化应激的影响

目的 研究罗格列酮对糖尿病大鼠肾组织氧化应激的影响.方法 36只雄性Wistar大鼠随机分为正常对照组(NC)、糖尿病组(DM)、糖尿病罗格列酮治疗组(DK).腹腔注射链脲佐菌素(STZ)诱导糖尿病模型,罗格列酮[5mg/(kg·d)]对DK组进行治疗性灌胃.8周末称取体重、肾重、肾重/体重,检测尿白蛋白排泄率(UAER)及尿肌酐;测定各组生化指标包括血糖(BG)、胆固醇(TC)、三酰甘油(TG)、血清肌酐(SCr);检测肾组织与尿中丙二醛(MDA)的含量及肾组织超氧化物歧化酶(SOD)、过氧化氢酶(CAT)与谷胱甘肽过氧化物酶(GSH-Px)活性;PAS染色作肾组织切片分析肾小球面积、肾小球体积及系膜区面积.结果 8周时,与DM组比较,DK组大鼠BG、TC、TG差异无显著性.DM组大鼠肾重、肾重/体重、UAEK、Ccr、肾小球面积、肾小球体积、系膜区面积较NC组均明显增加,DR组上述改变较DM组均明显减轻(P<0.05).DK组肾组织及尿中MDA含量明显低于DM组,SOD、CAT、GSH-Px活性明显高于DM组(P<0.05).结论 罗格列酮对糖尿病大鼠肾组织有明显保护作用.其机制部分可能与抑制肾组织氧化应激有关.